J. Balint

The Dual-Antigen Ad5 COVID-19 Vaccine Delivered as an Intranasal Plus Subcutaneous Prime Elicits Th1 Dominant T-Cell and Humoral Responses in CD-1 Mice

This study evaluates a dual-antigen Ad5 vaccine delivered via subcutaneous and intranasal routes in mice, showing that combined prime-only delivery elicits strong humoral and T-cell responses against SARS-CoV-2.

Complete Protection of Nasal and Lung Airways Against SARS-CoV-2 Challenge by Antibody Plus Th1 Dominant N- and S-Specific T-Cell Responses to Subcutaneous Prime and Thermally-Stable Oral Boost Bivalent hAd5 Vaccination in an NHP Study

hAd5 spike + nucleocapsid SC prime/oral boost vaccine elicits humoral and T-cell responses and protects rhesus macaques from SARS-CoV-2 challenge.

A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Dominant CD4+, CD8+ T-cell and Neutralizing Antibody Responses

This paper describes a bivalent hAd5 vaccine combining S-Fusion and N-ETSD antigens that elicits strong Th1-biased T-cell and neutralizing antibody responses in pre-clinical models.